Acute Liver Injury due to Glecaprevir/Pibrentasvir in a Patient with Chronic Hepatitis C Virus Infection without Cirrhosis

Ayushi Jain1 Khalid Mumtaz2

1 Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
2 Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

Address for correspondence Khalid Mumtaz, MBBS, MSc, Department of Clinical Medicine, Gastroenterology, Hepatology & Nutrition, Ohio State University Wexner Medical Center, Columbus, Ohio 43210, United States (e-mail: khalid.mumtaz@osumc.edu).

Introduction

Glecaprevir/pibrentasvir is a direct-acting antiviral oral agent used for treatment of pangenotypic hepatitis C virus (HCV) infections and has shown to achieve sustained virologic response rates of greater than 90% after 12 weeks of treatment. The combination of glecaprevir, a NS3/4A protease inhibitor, and pibrentasvir, a NS5A inhibitor, in a ribavirin-free regimen has demonstrated safety and effectiveness in patients without liver function test (LFT) impairment or with mild LFT impairment but is not indicated for use in patients with moderate-to-severe liver impairment.

There are few reports of hepatic decompensation with the use of glecaprevir/pibrentasvir in patients with existing decompensated cirrhosis and reactivation of hepatitis B virus (HBV) coinfection. Yoon et al reported a case of severe jaundice in a patient with compensated cirrhosis 12 weeks after initiation of glecaprevir/pibrentasvir that resolved 3 months after drug cessation. However, acute liver injury is rare in a non-cirrhotic patient without HBV coinfection with the use of glecaprevir/pibrentasvir. We report a unique case of acute liver injury in a patient with chronic HCV infection without cirrhosis 4 weeks after initiation of glecaprevir/pibrentasvir.

Case Report

A 43-year-old female patient with a past medical history of intravenous drug use was known to have contracted chronic HCV infection genotype 2B approximately 10 years ago. She had no clinical, biochemical, or imaging features of cirrhosis and was initiated on glecaprevir/pibrentasvir for treatment of chronic HCV. Four weeks after initiation of glecaprevir/pibrentasvir, she was admitted with worsening right upper quadrant (RUQ) abdominal pain with nausea. Physical exam revealed jaundice...
and mild tenderness in the RUQ without Murphy's sign. No stigmata of cirrhosis including ascites or hepatosplenomegaly were identified on exam. LFTs on admission revealed elevated total bilirubin of 6.8 mg/dL with a direct bilirubin of 4.3 mg/dL, and aspartate transaminase and alanine aminotransferase were 273 and 198 U/L, respectively. The remainder of the LFTs, international normalized ratio, and complete blood count were within normal range. Work up for autoimmune (antinuclear, antismooth muscle, antimitochondrial, and anti-liver-kidney microsome antibodies), viral (hepatitis A, B, and E), and metabolic (ceruloplasmin, iron studies) causes of liver disease were all negative. Liver ultrasound and magnetic resonance cholangiopancreatography revealed hepatic steatosis and diffuse gallbladder wall thickening and edema without biliary dilation or cholelithiasis. A list of the patient’s current medications was reviewed and no hepatotoxic drugs were identified. Surgical consultation was sought and acute acalculous cholecystitis was also ruled out.

Based on the temporal association of initiation of antiviral therapy for chronic HCV, a diagnosis of acute liver injury secondary to glecaprevir/pibrentasvir was concluded. Glecaprevir/pibrentasvir was discontinued and LFTs peaked 2 days later with rapid subsequent improvement. The pattern of improvement in LFTs is demonstrated in Fig. 1. On follow-up, 1 week after holding glecaprevir/pibrentasvir, LFTs had completely improved. HCV polymerase chain reaction (PCR) was shown to have improved from 139,268 copies/mL (reference range < 25) prior to initiation of glecaprevir/pibrentasvir to 425 copies/mL. We plan to monitor HCV PCR and consider alternate antiviral therapy including sofosbuvir/velpatasvir.

**Discussion**

We present a rare case of acute liver injury secondary to glecaprevir/pibrentasvir in a patient with HCV infection without cirrhosis. Acute liver injury due to the use of glecaprevir/pibrentasvir was concluded by the temporal association of drug initiation and subsequent rise in LFTs. It is further supported by improvement in LFTs shortly after discontinuation of glecaprevir/pibrentasvir. The Naranjo Probability Scale for Adverse Drug Events was used to estimate the probability that a drug was the cause of the acute liver injury. A score of 7 was calculated, consistent with a probable adverse drug reaction. This indicates that the reaction followed a reasonable recognized response to the suspected drug, was confirmed by withdrawal but not by exposure to the drug and could not be reasonably explained by the known characteristics of the patient’s clinical state.

The introduction of protease inhibitors such as glecaprevir/pibrentasvir brought a more favorable safety profile with primary biliary-fecal excretion. This combination carries a risk of HBV reactivation without concomitant HBV antiviral therapy and is contraindicated in patients with Child–Turcotte–Pugh B or C decompensated cirrhosis, prior history of hepatic decompensation, or use of atazanavir or rifampin. Previous literature describes a case of liver injury due to glecaprevir/pibrentasvir by Hammami et al in a patient with the absence of cirrhosis who developed acute liver injury that completely resolved after withdrawal of glecaprevir/pibrentasvir. Hara et al describe a second case of acute liver injury with development of hepatic...
encephalopathy in a patient with concomitant inactive HBV coinfection 6 weeks after glecaprevir/pibrentasvir initiation that later resolved with discontinuation of therapy. The mechanism of liver injury in the absence of cirrhosis with glecaprevir/pibrentasvir is unknown. As glecaprevir is largely metabolized by the liver, there may be an increased risk of potential drug–drug interactions and subsequent liver injury. The production of toxic or immunogenic metabolites is one proposed source of injury.

This case report highlights a probable adverse drug reaction causing acute liver injury in a patient with chronic HCV due to glecaprevir/pibrentasvir. Our findings endorse the need to remain vigilant for the risk of liver injury after initiation of glecaprevir/pibrentasvir even without a diagnosis of cirrhosis. When glecaprevir/pibrentasvir-associated liver injury is identified, cessation of therapy has shown to lead to subsequent improvement in LFTs within weeks, as in our case. We emphasize monitoring patient symptoms and LFTs while on glecaprevir/pibrentasvir for chronic HCV infection, regardless of the status of preexisting liver cirrhosis.

Note
Informed consent was obtained for this case report.

Authors’ Contributions
A.J. and K.M. wrote the manuscript. K.M. is the article guarantor.

Funding
None.

Conflict of Interest
None declared.

References
2 FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease. U.S. Food and Drug Administration; 2019
5 Highlights of Prescribing Information. FDA 2017